These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 27603672)

  • 1. The Role of IL28B Genotype in HCV-RNA Baseline Levels.
    Boglione L; Cusato J; Di Perri G; D'Avolio A
    Intervirology; 2016; 59(2):67-68. PubMed ID: 27603672
    [No Abstract]   [Full Text] [Related]  

  • 2. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Imamura M; Ochi H; Kamatani N; Nakamura Y; Chayama K
    Gut; 2011 Feb; 60(2):261-7. PubMed ID: 21068134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
    Bochud PY; Bibert S; Negro F; Haagmans B; Soulier A; Ferrari C; Missale G; Zeuzem S; Pawlotsky JM; Schalm S; Hellstrand K; Neumann AU; Lagging M
    J Hepatol; 2011 Nov; 55(5):980-8. PubMed ID: 21354446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.
    Stenkvist J; Sönnerborg A; Weiland O
    J Viral Hepat; 2013 Mar; 20(3):193-9. PubMed ID: 23383658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
    Sarrazin C; Susser S; Doehring A; Lange CM; Müller T; Schlecker C; Herrmann E; Lötsch J; Berg T
    J Hepatol; 2011 Mar; 54(3):415-21. PubMed ID: 21112657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
    Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
    Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
    J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
    J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
    Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms.
    Ling Q; Chen J; Zhou H; Zhong J; Chen Y; Ye Q; Zhuo Y; Min N; Shang B
    Arch Virol; 2015 Apr; 160(4):1105-12. PubMed ID: 25687192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.
    Kawaoka T; Hayes CN; Ohishi W; Ochi H; Maekawa T; Abe H; Tsuge M; Mitsui F; Hiraga N; Imamura M; Takahashi S; Kubo M; Tsunoda T; Nakamura Y; Kumada H; Chayama K
    J Hepatol; 2011 Mar; 54(3):408-14. PubMed ID: 21112660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C.
    Atsukawa M; Tsubota A; Shimada N; Abe H; Kondo C; Itokawa N; Nakagawa A; Iwakiri K; Kawamoto C; Aizawa Y; Sakamoto C
    Dig Liver Dis; 2014 Aug; 46(8):738-43. PubMed ID: 24880716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.